Helsinn brings cancer pain management option to China

With the help of Mundipharma China Pharmaceutical, ALOXI IV will be used for the prevention of chemotherapy-induced nausea and vomiting (CINV) in China

Swiss pharma company, Helsinn Group, has worked with Chinese pain management firm, Mundipharma China Pharmaceutical, to make ALOXI IV available in China.

This is Helsinn’s first cancer supportive care product to be launched in the Chinese market, and for which Mundipharma China Pharmaceutical has exclusive marketing, promotion and sales rights.

This product was approved by the National Medical Products Administration (NMPA) in November 2018.

The launch of ALOXI IV in China has also seen the initiation of a long co-detailing collaboration with Helsinn Pharmaceuticals (Beijing) in the municipality of Shanghai for ALOXI IV and other future cancer care products in the Chinese market.

Andrea Meoli, Helsinn Group Chief Commercial Officer, said: “Since ALOXI’s launch in the other countries, it has been effectively used for the prevention of chemotherapy-induced nausea and vomiting (CINV), helping to define the standard of care for the condition, and we are delighted that it is now becoming available to patients in China.”

Peter Wang, General Manager, Mundipharma Pharmaceutical Greater China, said: “I believe there will be more CINV products with cutting-edge technologies to be brought into China market through the joint efforts of both sides, which will benefit more Chinese cancer patients.”

Companies